Y Ariyoshi

6.8k total citations · 2 hit papers
127 papers, 5.5k citations indexed

About

Y Ariyoshi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Y Ariyoshi has authored 127 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 53 papers in Molecular Biology and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Y Ariyoshi's work include Lung Cancer Research Studies (42 papers), Lung Cancer Treatments and Mutations (30 papers) and Cancer therapeutics and mechanisms (27 papers). Y Ariyoshi is often cited by papers focused on Lung Cancer Research Studies (42 papers), Lung Cancer Treatments and Mutations (30 papers) and Cancer therapeutics and mechanisms (27 papers). Y Ariyoshi collaborates with scholars based in Japan, United States and United Kingdom. Y Ariyoshi's co-authors include Masahiro Fukuoka, Kiyoyuki Furuse, Masaaki Kawahara, Nobuyuki Katagami, Yoshiki Takada, Shinzoh Kudoh, M. Fukuoka, H Nishikawa, Takashi Takahashi and Shunichi Negoro and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Y Ariyoshi

122 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung Cancer

1999 1.1k citations Kiyoyuki Furuse, Masahiro Fukuoka et al. Journal of Clinical Oncology profile →
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

2006 515 citations Yasuo Ohashi, Kaoru Kubota et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y Ariyoshi Japan	31	3.2k	2.8k	2.0k	697	427	127	5.5k
Stephen L. Graziano United States	39	2.8k 0.9×	2.9k 1.0×	1.3k 0.6×	559 0.8×	695 1.6×	117	5.2k
Shunichi Negoro Japan	37	4.9k 1.5×	3.8k 1.3×	2.3k 1.2×	1.4k 2.0×	476 1.1×	163	6.2k
Neal Ready United States	36	4.2k 1.3×	2.8k 1.0×	1.1k 0.5×	1.1k 1.6×	481 1.1×	160	5.7k
Miyako Satouchi Japan	37	2.8k 0.9×	3.5k 1.3×	900 0.5×	344 0.5×	701 1.6×	171	4.8k
Masahiko Higashiyama Japan	45	2.1k 0.7×	3.6k 1.3×	1.5k 0.8×	400 0.6×	947 2.2×	202	6.2k
Tetsuro Kodama Japan	39	1.9k 0.6×	2.1k 0.7×	1.0k 0.5×	830 1.2×	338 0.8×	156	4.4k
Kazumasa Noda Japan	31	4.3k 1.3×	3.7k 1.3×	2.0k 1.0×	1.5k 2.1×	602 1.4×	112	6.3k
Thomas E. Stinchcombe United States	41	3.9k 1.2×	3.7k 1.3×	1.7k 0.9×	312 0.4×	824 1.9×	215	6.9k
Wilfried Eberhardt Germany	39	4.2k 1.3×	5.3k 1.9×	1.7k 0.8×	429 0.6×	892 2.1×	239	7.6k
Shinzoh Kudoh Japan	27	4.0k 1.2×	4.5k 1.6×	1.3k 0.6×	278 0.4×	489 1.1×	84	5.7k

Countries citing papers authored by Y Ariyoshi

Since Specialization

Citations

This map shows the geographic impact of Y Ariyoshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y Ariyoshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y Ariyoshi more than expected).

Fields of papers citing papers by Y Ariyoshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y Ariyoshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y Ariyoshi. The network helps show where Y Ariyoshi may publish in the future.

Co-authorship network of co-authors of Y Ariyoshi

This figure shows the co-authorship network connecting the top 25 collaborators of Y Ariyoshi. A scholar is included among the top collaborators of Y Ariyoshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y Ariyoshi. Y Ariyoshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matsuda, Masaya, et al.. (2025). Essential roles of mechanistic target of rapamycin in the induction of steroid resistance in group 2 innate lymphoid cells and severe asthma. Journal of Pharmacology and Experimental Therapeutics. 392(11). 103744–103744.

Kubota, Kaoru, Hiroshi Sakai, Nobuyuki Yamamoto, et al.. (2010). A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(5). 702–706. 21 indexed citations

Nishimura, Yasumasa, Kazuhiko Nakagawa, Koji Takeda, et al.. (2007). Phase I/II Trial of Sequential Chemoradiotherapy Using a Novel Hypoxic Cell Radiosensitizer, Doranidazole (PR-350), in Patients With Locally Advanced Non–Small-Cell Lung Cancer (WJTOG-0002). International Journal of Radiation Oncology*Biology*Physics. 69(3). 786–792. 26 indexed citations

Sugiura, Takahiko, Y Ariyoshi, Shunichi Negoro, et al.. (2005). Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Investigational New Drugs. 23(4). 331–337. 26 indexed citations

Kudoh, Satoshi, Satoaki Nakamura, Takashi Nakano, et al.. (2005). Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: A phase II trial of West Japan Thoracic Oncology Group. Lung Cancer. 49(2). 263–269. 11 indexed citations

Negoro, Shunichi, N Masuda, Y Takada, et al.. (2003). Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer. 88(3). 335–341. 121 indexed citations

Kawahara, Masaaki, Y Ariyoshi, Masahiro Fukuoka, & Kiyoyuki Furuse. (2000). Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group. Critical Reviews in Oncology/Hematology. 36(1). 9–12. 1 indexed citations

Arai, Yasuaki, et al.. (1999). Phase II Study of Combined Administration of 5-Fluorouracil, Epirubicin and Mitomycin-C by Hepatic Artery Infusion in Patients with Liver Metastases of Gastric Cancer. Oncology. 57(3). 216–223. 30 indexed citations

Mitsudomi, Tetsuya, S. Hatooka, Masayuki Shinoda, et al.. (1998). Clinical Implications of p53 Autoantibodies in the Sera of Patients With Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 90(20). 1563–1568. 46 indexed citations

10.

Kudoh, Satoshi, Yasuhiro Fujiwara, Y Takada, et al.. (1998). Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.. Journal of Clinical Oncology. 16(3). 1068–1074. 139 indexed citations

11.

Kuwabara, Masayoshi, Nobuhiro Shibata, & Y Ariyoshi. (1997). [Lung cancer: progress in diagnosis and treatment. I. Diagnosis and physiopathology: 4. Progress in the study of tumor markers].. PubMed. 86(1). 20–6. 2 indexed citations

12.

Kudoh, Satoshi, Toshiyuki Sawa, Naotsugu Kurihara, et al.. (1996). Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 38(0). S89–S95. 5 indexed citations

13.

Hida, Toyoaki, Ryuzo Ueda, Yoshitaka Sekido, et al.. (1994). Ectopic expression of c-kit in small-cell lung cancer. International Journal of Cancer. 57(S8). 108–109. 28 indexed citations

14.

Yoshida, Takashi, Kazuo Ota, Yutaka Yoshida, et al.. (1993). Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial. Cancer Chemotherapy and Pharmacology. 31(6). 445–448. 1 indexed citations

15.

Nishida, Keiko, Ryuzo Ueda, K Sakakibara, et al.. (1993). Characterization of OM‐B Monoclonal Antibody‐defined Antigen Associated with Mucinous Type Human Ovarian Tumor. Japanese Journal of Cancer Research. 84(1). 65–74. 2 indexed citations

16.

Kimura, Shigeki, et al.. (1993). Development and application of an enzyme immunoassay for tenascin. Clinica Chimica Acta. 219(1-2). 15–22. 17 indexed citations

17.

Iida, Shinsuke, Midori Saito, Masao Seto, et al.. (1992). Phenotypic and genotypic characterization of 14 leukemia and lymphoma cell lines with 11q23 translocations. Leukemia Research. 16(12). 1155–1163. 15 indexed citations

18.

Fukuoka, M., H Niitani, Atsushi Suzuki, et al.. (1992). A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.. Journal of Clinical Oncology. 10(1). 16–20. 374 indexed citations

19.

Ariyoshi, Y & Ota K. (1989). [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].. PubMed. 16(4 Pt 2-2). 1379–85. 1 indexed citations

20.

Ariyoshi, Y & Ota K. (1989). Preclinical and clinical evaluation of toxicities and antitumor activities of cisplatin analogues. Gan to kagaku ryōhō. 16. 1379–1385. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact